This article is available to subscribers. Subscribe now. Already have an account? Sign in

Medical IntelligenceFree PreviewArchive

Indomethacin-Responsive Hypercalcemia in a Patient with Renal-Cell Adenocarcinoma

List of authors.
  • Harmar D. Brereton, M.D.,
  • Perry V. Halushka, M.D., Ph.D.,
  • R. Wayne Alexander, M.D., Ph.D.,
  • Donald M. Mason, M.D.,
  • Harry R. Keiser, M.D.,
  • and Vincent T. DeVita, Jr., M.D.

IN recent reports, Powell et al. described nonparathyroid humoral hypercalcemia in patients with neoplastic disease,1 and Tashjian and his colleagues have suggested the possible role of prostaglandins, or other unidentified substances, in cases of neoplastic disease as the cause of hypercalcemia not explained by bone metastases or detectable parathyroid hormone-like peptides.2 Hypercalcemia in mice bearing a prostaglandin-producing fibrosarcoma has been treated successfully by Tashjian and his co-workers2 with indomethacin, a potent inhibitor of prostaglandin synthesis.3 The following case adds support to the suggestion that some forms of hypercalcemia secondary to neoplastic disease are responsive to indomethacin, and may be due . . .

Author Affiliations

From the Medicine and Radiation Branches, National Cancer Institute, the Section on Experimental Therapeutics, National Heart and Lung Institute, and the United States Public Health Service Hospital, San Francisco, Cal. (address reprint requests to Dr. Brereton at the Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20014).

Print Subscriber? Activate your online access.